Galvanize Therapeutics, a Redwood City, California company developing minimally invasive pulsed electric field (PEF) ablation technologies, said on Monday that it had closed an oversubscribed $130 million Series D led by HealthQuest Capital. The company announced the round on 16 November 2026, framing it as follow-on capital for the U.S. commercial expansion of its Aliya system, which Galvanize says has now been used in more than 4,000 procedures. No valuation was disclosed.
Who put in the money
HealthQuest Capital led the Series D, joined by two new investors, Olympus Innovation Ventures and Braidwell LP. The existing syndicate also participated, including Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company, and T. Rowe Price Associates, Inc. According to Captables, the Series D is roughly 30% larger than the $100 million Series C that Sofinnova Partners led in September 2025. The round adds Galvanize to the current crop of recently funded healthcare startups and to the list of Series D startups now putting commercial-stage capital to work.
What Galvanize Therapeutics is building
Galvanize develops minimally invasive PEF ablation technologies. The company describes PEF as a nonpharmacologic, nonthermal intervention that uses short-duration, highly focused electrical pulses. Its commercial product, Aliya, is 510(k) cleared in the United States for surgical ablation of soft tissue only. It carries no disease-specific indication, and it is not sold outside the United States. The company has described a broader vision for PEF across oncology and chronic disease, but that vision is distinct from Aliya’s current clearance: any immune-response benefit has not been established, and the 4,000 procedures the company cites do not constitute a cancer indication. A second program, RheOx, is being advanced for chronic bronchitis and remains investigational in the United States.
Alongside procedure volume, Galvanize points to FDA clearance and launch of the next-generation Aliya EX, more than 300 patients enrolled in its PROPEL registry, and more than 40 peer-reviewed publications. Captables reports that the first commercial Aliya EX procedures were announced in August, following FDA clearance in May 2026. The company said the new capital will fund continued U.S. commercial expansion of Aliya, clinical evidence generation, the RheOx chronic bronchitis program, and development of next-generation PEF products and platforms — a spending mix that puts it closer to commercial-stage device operators than to the earlier-stage biotech startups tracking toward first-in-human work.
What the raise means for vendors
The stated use of funds is unusually legible for sellers. U.S. commercial expansion of a cleared device implies field sales hiring, territory planning, sales enablement and CRM, reimbursement and market-access support, hospital contracting, capital-equipment logistics, and service infrastructure for installed systems. Evidence generation points to clinical operations vendors, registry and data-management platforms, biostatistics, medical writing, and publication support, with the PROPEL registry already running. The RheOx program implies regulatory consulting and trial-site services, while next-generation platform development implies engineering, electronics and contract manufacturing partners.
Because Aliya is sold only in the United States, buyers should expect domestic-first procurement rather than an international rollout, and quality, regulatory, and post-market surveillance suppliers familiar with 510(k)-cleared devices will be the better fit than those pitching ex-U.S. market entry. Redwood City keeps the company inside a dense Bay Area supplier base, a pattern common among U.S.-based startups raising growth rounds. Vendors who time outreach to the weeks after a close tend to reach budget owners before plans harden, and Galvanize now joins the list of newly funded startups Growth List tracks in its weekly Funded This Week coverage, with fresh capital to deploy this week.
Free: top-10 + totals • Paid: full list + verified contacts
This is free coverage of a funding event. Growth and Scale unlock every newly funded company we track each week, plus verified decision-maker contacts.
Sources: Galvanize Therapeutics via PR Newswire, 16 November 2026; MassDevice; Captables. Featured image: the downtown arch in Redwood City, California, by Coolcaesar / Wikimedia Commons, CC BY 4.0, via Wikimedia Commons.